Biotech Analyst Ding, along with Key Opinion Leader Daniel Elling, Principal at Federal Health Policy Strategies, discuss recent legislative actions relevant to Xphozah, when the bill could be signed into law and the expected impact to Ardelyx (ARDX) on an Analyst/Industry conference call to be held on October 25 at 11 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARDX:
- Ardelyx shares data on IBSRELA via oral presentation, posters
- Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
- Biotech Alert: Searches spiking for these stocks today
- Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
- Ardelyx price target raised to $10.50 from $8.50 at Ladenburg